Table 2 |
||
| Follow-up and final disposition of subjectsa | ||
| Women, n | Men, n | |
| Total subjects | 1,390 | 1,158 |
| CD diagnosed by histology before enrolment | 0 | 1 |
| Abnormal composite TG2/DGP IgA/IgG, and TG2 IgA, or DGP IgA or IgG | 51 | 56 |
| Findings diagnostic/supportive of untreated CD | ||
| Histological diagnosis: Intestinal villous atrophy, crypt hyperplasia, and IELs | ||
| Prompted by current study, 2010 | 6 | 4 |
| During standard medical care between 2004 and 2009 | 4 | 2 |
| Serological diagnosis: confirmation of multiple CD serological abnormalities | ||
| No supporting histological evidence obtained | 2 | 3 |
| Treating doctor excluded CD because patient was asymptomatic | 0 | 2 |
| Findings equivocal for CD | ||
| Intestinal IELs +/− mild focal villous atrophy, or villous atrophy and crypt hyperplasia without IELs | 0 | 3 |
| Findings excluded/were not supportive of CD | ||
| Normal intestinal histology without serological testing | 2 | 5 |
| Serological exclusion: CD serological abnormalities not replicated | 7 | 8 |
| Genotyping exclusion: testing for HLA DQ2.5/8/2.2 negative | 0 | 1 |
| Follow-up not possible or not undertaken | ||
| Treating doctor did not investigate further as subject asymptomatic and/or performed blood tests unrelated to CD | 1 | 5 |
| Subject deceased and CD not diagnosed pre-mortem | 8 | 5 |
| Subject declined follow-up medical review | 16 | 11 |
| Subject could not be contacted; lost to follow-up | 5 | 7 |
| CD cases estimated by serogenetic modeling, range | 12 to 26 | 12 to 16 |
| Lower 95% CI for CD cases based on TG2+ EMA+ | 11 | 12 |
Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; IEL, Intra-epithelial lymphocyte; Ig, immunoglobulin; TG, transglutaminase.
aData are n, unless otherwise stated.
Anderson et al.
Anderson et al. BMC Medicine 2013 11:188 doi:10.1186/1741-7015-11-188
